PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary ...

A recent study reveals that age plays a significant role in the outcomes of intermittent fasting. Researchers from Technical ...

PHC has partnered with CCRM to boost cell quality with advanced T-cell expansion solutions. Takeaway Points  PHC has ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...

TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia. See ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR T cell therapy program for autoimmune diseases.